Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs …

The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …

Executive summary Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult
to treat than drug-susceptible ones, and threaten global progress towards the targets set by …

Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America …

Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to
rifampicin and other TB medicines challenge patient survival and public health. The World …

The World Health Organization (WHO) has produced this WHO operational handbook on
tuberculosis to provide practical advice to complement the latest WHO consolidated …

Drug-resistant tuberculosis is a major public health concern in many countries. Over the past
decade, the number of patients infected with Mycobacterium tuberculosis resistant to the …

Tuberculosis (TB) is one of the oldest known human diseases and is transmitted by the
bacteria Mycobacterium tuberculosis (Mtb). TB has a rich history with evidence of TB …

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis
(MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients …